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ABSTRACT
Introduction: Sleepiness is a cardinal symptom in
obstructive sleep apnoea (OSA) but most patients have
unspecific symptoms. Arterial stiffness, evaluated by
pulse wave velocity (PWV), is related to atherosclerosis
and cardiovascular (CV) risk. Arterial stiffness was
reported to be higher in patients with OSA, improving
after treatment with continuous positive airway
pressure (CPAP). This study aims to assess whether
the same effect occurs in patients with OSA and
without sleepiness.
Methods and analysis: This observational study
assesses the CV effect of CPAP therapy on a cohort of
patients with moderate-to-severe OSA; the effect on the
subcohorts of sleepy and non-sleepy patients will be
compared. A systematic and consecutive sample of
patients advised CPAP therapy will be recruited from a
single outpatient sleep clinic (Centro Hospitalar de
Lisboa Central—CHLC, Portugal). Eligible patients are
male, younger than 65 years, with confirmed
moderate-to-severe OSA and apnoea–hypopnea index
(AHI) above 15/hour. Other sleep disorders, diabetes
or any CV disease other than hypertension are
exclusion criteria. Clinical evaluation at baseline
includes Epworth Sleepiness Scale (ESS), and
sleepiness is defined as ESS above 10. OSA will be
confirmed by polygraphic study (cardiorespiratory,
level 3). Participants are advised to undertake an
assessment of carotid-femoral PWV (cf-PWV) and
24 hours evaluation of ambulatory blood pressure
monitoring (ABPM), at baseline and after 4 months of
CPAP therapy. Compliance and effectiveness of CPAP
will be assessed. The main outcome is the variation of
cf-PWV over time.
Ethics and dissemination: This protocol was
approved by the Ethics Committees of CHLC (reference
number 84/2012) and NOVA Medical School
(number36/2014/CEFCM), Lisbon. Informed, written
consent will be obtained. Its results will be presented at
conferences and published in peer-reviewed journals.
Trial registration number: NCT02273089;
Pre-results.
BACKGROUND
Obstructive sleep apnoea (OSA), if left
untreated, is associated with high cardiovas-
cular (CV) morbidity and mortality.1–3
The diagnosis of OSA syndrome is based on
the presence of symptoms suggestive of the
disorder, with conﬁrmation by polygraphic
sleep study.4 5 The Epworth Sleepiness Scale
(ESS) is a validated questionnaire that evalu-
ates the presence of excessive daytime somno-
lence.6 Other symptoms besides sleepiness
are non-speciﬁc (decreased concentration,
irritability),4 5 hampering diagnosis.
Continuous positive airway pressure
(CPAP) is the standard therapy for patients
with symptomatic OSA, but CPAP therapy for
asymptomatic patients is consensual only
when the apnoea–hypopnea index (AHI) is
above 30/hour.7
In some studies, greater severity in polysom-
nographic parameters has been reported in
sleepy patients in comparison with those who
are not sleepy.8 9
Strengths and limitations of this study
▪ This study allows us to obtain new evidence on
the effectiveness of continuous positive airway
pressure (CPAP) in decreasing cardiovascular
risk in sleepy and non-sleepy male patients with
obstructive sleep apnoea (OSA).
▪ The strengths of this protocol are a controlled
and clinic-based setting, the use of standardised
instruments to characterise OSA and sleepiness
and the use of standardised quantitative early
indicators of cardiovascular risk (carotid-femoral
pulse wave velocity, cf-PWV).
▪ This observational study has the limitations of con-
venience, non-randomised sample and the exclu-
sion of patients with mild OSA or older patients.
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Considering the relationship between OSA and CV
disease, namely arterial hypertension or CV risk, it is less
evident in patients with fewer symptoms. The effect of
CPAP in lowering the blood pressure (BP) levels seems
greater in patients with more severe OSA and sleepiness
than in those without it.10
Changes in arterial stiffness are measurable and are
one of the earliest manifestations of functional and
structural damage to the vessel wall in the process of ath-
erosclerosis. Arterial stiffness, evaluated by pulse wave
velocity (PWV), is used as an early marker of organ
damage in patients with hypertension.11 It predicts CV
events, beyond classical CV risk factors, and can be con-
sidered as an intermediate end point for CV events.12
Carotid-femoral PWV (cf-PWV), that is, the speed of the
pulse as it travels from the heart to the carotid and the
femoral artery, is the most commonly used non-invasive
method to assess arterial stiffness and is considered to
be the gold standard.12 13
Increased arterial stiffness depends on various condi-
tions, of which BP and ageing prevail, but also depends
on other CV risk factors.
cf-PWV value is augmented in patients with OSA, and
even in those without high BP.14 15 It is increased even
in the less symptomatic, severe patients. However, there
is an improvement after treatment with CPAP,16 but the
effect in patients without sleepiness is less well known
and still controversial.17
This research protocol aims to assess the variation of
arterial stiffness in two cohorts of patients with OSA,
either sleepy or non-sleepy, while undergoing treatment
with CPAP. We hypothesise that a measurable improve-




This project involves the prospective and observational
study of a systematic, consecutive and non-randomised
sample of adult male patients diagnosed with OSA and
advised CPAP therapy, recruited from a single outpatient
sleep clinic (Centro Hospitalar de Lisboa Central—
CHLC, Lisbon, Portugal).
The sample is divided into two cohorts according to
the ESS and the effect of CPAP therapy on sleepy
(ESS>10) and non-sleepy (ESS≤10) patients will be com-
pared (ﬁgure 1).
The primary outcome is the variation of cf-PWV after
therapy with CPAP. The effect of a 4-month trial of
CPAP therapy is assessed. For ethical reasons, each
patient will act as its own control.
Obesity and metabolic syndrome are common ﬁndings
in OSA, and possible changes of metabolic parameters
after CPAP are relevant.18
Secondary outcomes are ambulatory blood pressure
monitoring (ABPM) variations and metabolic changes
after treatment with CPAP.
The study is exploratory in nature and is based on a
convenient sample, limited by the number of eligible
patients consenting to participate. The effective
sample size estimated for the primary outcome was 70
patients in order to demonstrate a reduction on
cf-PWV from 12 to 11 m/s (from baseline to 4 months
on CPAP), with 95% CI and power 80%. Based on the
previous assessment of the institutional experience on
compliance with CPAP and with outpatient clinic con-
sultations, the recruited sample was increased in 15%
to obtain a ﬁnal sample of 80 patients.
Recruitment started on October 2012 and data collec-
tion is expected to end by June 2016.
Inclusion criteria
Patients referred to the Outpatient Sleep Clinic of the
Pneumology Department, CHLC, Lisbon, because of
snoring or other symptoms suggestive of OSA, were eli-
gible for the study if they met the following criteria:
males, younger than 65 years old, living in Greater
Figure 1 Study design. ABPM, ambulatory blood pressure
monitoring; CF-PWV, carotid-femoral pulse wave velocity;
CPAP, continuous positive airway pressure; ESS, Epworth
Sleepiness Scale; OSA, obstructive sleep apnoea.
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Lisbon and with conﬁrmed moderate-to-severe OSA
(AHI>15/hour). To conﬁrm this, on the ﬁrst consult-
ation, data on anamnesis and clinical examination were
collected and the Epworth questionnaire was used.
Exclusion criteria
Patients are excluded if they have a history of CV
events, established heart disease (beyond arterial
hypertension) and peripheral vascular disease. Patients
who are smoking (over 10 units pack/year) or consum-
ing alcohol (>80 g/day) are not accepted. Other severe
chronic diseases (assessed by chronic use of medica-
tion), chronic ingestion of hypnotics or other sleep dis-
orders (clinically identiﬁed) are among the exclusion
criteria.
Patients with diabetes are excluded, as they might
have vascular involvement.
However, patients with some comorbidities namely
hypertension and metabolic syndrome are allowed.
Patients with antihypertensive medication and undergo-
ing treatment of dyslipidemia are allowed as well.
Baseline evaluation
The Outpatient Sleep Clinic protocol for patients
referred due to snoring or other symptoms suggestive of
OSA require clinical evaluation, blood test, ECG and
sleep study.
ESS will be applied by the principal investigator, and
the presence of comorbidities and pharmacotherapy in
progress is evaluated.
The collection of data regarding duration of
comorbidity or pharmacotherapy has not been consid-
ered since including these two factors as liable interven-
ing factors would greatly increase the sample size.
Anthropometric data regarding adiposity and vital
signs are collected. Body mass index (BMI) is calculated
as weight (kg) divided by height (m) squared.
BP will be measured while the patient is in a quiet
room, using a semiautomatic device (Omron
HEM-907XL, Omron Healthcare, Bannockburn, Illinois,
USA) with an appropriate cuff. The patient should not
have taken stimulants 3 hours prior to BP measurement.
Two measurements are taken with a minimum of 3 min
interval and the average is considered. When large dif-
ferences existed among the measurements, additional
measurements were performed.
The analytical screening evaluation includes glycated
haemoglobin, fasting glucose, total cholesterol, high-density
lipoprotein, low-density lipoprotein and triglycerides; for in
patients with high levels of fasting glucose, an oral glucose
tolerance test will be performed. Dyslipidaemia, glucose
intolerance and metabolic syndrome are diagnosed accord-
ing to current guidelines.19
An ECG (Page Writer TC 30, Philips, Eindhoven,
Netherlands) will be performed by the same techni-
cians, as per institutional protocol.
Sleep study
To conﬁrm the diagnosis of OSA, patients will submit
to a polygraphic cardiorespiratory sleep study type 3
(Embletta system, Broomﬁeld, USA), a portable equip-
ment that performs continuous recording from a nasal
cannula (pressure and ﬂow), thoracic–abdominal
motion, pulse oximetry, ECG and a body position
sensor. Results from the sleep studies are analysed by
two trained technicians using standard criteria.20
Ambulatory blood pressure monitoring
All participants will undergo 24 hours BP monitoring using
an ABPM device—Spacelabs model 90207 (Issaquah,
Washington, USA), according to the current guidelines.
Patients are classiﬁed as normotensive if the average systolic
and diastolic BP values obtained by the ABPM are within
normal limits and are classiﬁed as hypertensive if already
on antihypertensive medication or if the average BP values
obtained from the ABPM are above ≥130 mm Hg for sys-
tolic and/or ≥80 mmHg for diastolic.11
Pulse wave velocity
Non-invasive assessment of cf-PWV (Complior, Colson,
Paris, France) will be performed by the same operator. For
this, the investigators followed the recently published
expert consensus document.21 In a few words, the meas-
urement is done at the right common carotid and the
right common femoral artery after 10 min rest in supine
position. Two pressure waveforms were transcutaneously
recorded at the base of the neck for the right common
carotid artery and over the right femoral artery. The pulse
transit time was determined as the average of 10 consecu-
tive beats. The straight line distance between the measure-
ment sites is obtained by surface measurement, with the
patient in the supine position. cf-PWV is calculated as the
ratio of distance to transit time. In order to normalise
cf-PWV values according to the arterial pathway, the
threshold of 10 m/s for cf-PWV evaluated by the full direct
carotid-to-femoral distance was considered.21
Standard CPAP intervention
According to the current clinical recommendations,4
patients with moderate or severe OSA are offered therapy
with non-invasive ventilation by CPAP. Additionally, patients
receive counselling on sleep hygiene.
An auto-CPAP device (ResMed S9 AutoSet, California,
USA) is used. CPAP will be titrated for 3 nights. The
deﬁnitive value of CPAP is the amount of pressure that
eliminates events in ∼95% of the total sleep time (95th
centile), once conﬁrmed that there is no signiﬁcant
leakage the nasal mask is used.22
Patients will be assessed monthly for compliance and
effectiveness of the intervention. Compliance to the
CPAP is measured using the data from the CPAP card; a
patient is considered to be in compliance when using
CPAP at least 4 hours/day (average) in at least 70% of
nights. CPAP is considered effective if the AHI falls
below 5/hour.23
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The presence of nasal symptoms or changes on the
equipment will be taken into account.
Follow-up assessments
After 4 months of standard CPAP intervention,
patients will undergo a clinical evaluation, including
ESS and analytical evaluation, similar to the one on
baseline. BMI, ABPM and cf-PWV will be assessed, as
well as compliance to CPAP and the effectiveness of
CPAP therapy.
At any point of the study, patients will be excluded
from follow-up if do not comply with CPAP, if signiﬁcant
weight loss (>10%) occurs,4 if new drugs are prescribed
or if new diseases are diagnosed.
Statistical analyses
The primary outcome measure (cf-PWV) is compared
before and after the therapy with CPAP for 4 months.
Analysis is performed as per intention to treat.
Continuous variables are described with median and
IQR (25th–75th centile) or extreme values, as previous
evaluations have evidenced that a normal distribution of
values was not to be expected. Data of sleepy and non-
sleepy patients at each evaluation are compared using the
Mann-Whitney test. Categorical variables are described as
percentage and are compared with Pearson’s χ2 test or
Fisher’s exact test; stratiﬁed Mantel-Haenszel analysis is
performed as appropriate.
The categorised outcome measure (using the thresh-
old of 10 m/s for cf-PWV21) is used to estimate the inci-
dence rates of the outcomes and relative risk estimates,
both with 95% CIs.
Measurements on the cohort before and after
4 months of CPAP therapy are analysed using general-
ised linear mixed-effects models for repeated longitu-
dinal data, to explore associations between outcomes
and exposures, in order to assess factors inﬂuencing the
success of the intervention.
DISCUSSION
The results of this study will disclose differences in the
CV risk and the response to CPAP therapy among
patients with and without daytime sleepiness. In the sub-
group of less-symptomatic patients, the beneﬁts of CPAP
have yet to be identiﬁed.
This observational study protocol has the limita-
tions of convenience, non-randomised sample, and
the exclusion of patients with mild OSA or older
patients. The strengths of this protocol are the con-
trolled clinic-based setting, the use of standardised
instruments to characterise OSA and sleepiness, and
the use of standardised quantitative early indicators
of CV risk (cf-PWV), a useful indicator of subclinical
CV disease.
Dissemination
The study has been registered as STIFFSLEEP at
ClinicalTrials.gov (ID: NCT02273089). Informed, written
consent will be obtained. Results will be presented at
conferences and published in peer-reviewed journals.
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